| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Hans Joachim Deeg | Q75039559 |
| P2093 | author name string | Rachel B Salit | |
| P2860 | cites work | Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT | Q24685958 |
| Lenalidomide therapy in myelofibrosis with myeloid metaplasia | Q33370821 | ||
| Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic | Q33371553 | ||
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
| Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). | Q33393151 | ||
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 | ||
| Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study | Q33394025 | ||
| Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis | Q33400683 | ||
| Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation | Q33406990 | ||
| Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls | Q33843390 | ||
| Outcome of transplantation for myelofibrosis | Q34015474 | ||
| IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. | Q34562170 | ||
| Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. | Q35608022 | ||
| The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation | Q35849342 | ||
| How to manage the transplant question in myelofibrosis | Q35865676 | ||
| Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. | Q35937081 | ||
| Hematopoietic cell transplantation for chronic myeloproliferative disorders | Q36661563 | ||
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 | ||
| A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis | Q83388958 | ||
| The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries | Q84065231 | ||
| SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival | Q84962229 | ||
| Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation | Q87247099 | ||
| Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. | Q37457111 | ||
| Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes | Q37504482 | ||
| How I treat myelofibrosis | Q37825719 | ||
| New mutations and pathogenesis of myeloproliferative neoplasms. | Q37886439 | ||
| Management of myelofibrosis | Q37967277 | ||
| The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. | Q40463923 | ||
| Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis | Q42840838 | ||
| Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis | Q43075410 | ||
| The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. | Q43162409 | ||
| Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q43265365 | ||
| Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis | Q43684702 | ||
| Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia | Q43904556 | ||
| Mutations and prognosis in primary myelofibrosis | Q44429606 | ||
| Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). | Q44707716 | ||
| Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis | Q45278082 | ||
| Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type | Q47174502 | ||
| Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia | Q47868737 | ||
| Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. | Q51023659 | ||
| Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. | Q53099028 | ||
| Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. | Q53136705 | ||
| Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. | Q53147067 | ||
| Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. | Q53166045 | ||
| Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. | Q53493942 | ||
| JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. | Q54374933 | ||
| Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. | Q54646707 | ||
| Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients | Q68002896 | ||
| A prognostic classification of myelofibrosis with myeloid metaplasia | Q68020265 | ||
| Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation | Q68876730 | ||
| Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients | Q70173636 | ||
| Stem cell transplantation for myelofibrosis: a report from two Canadian centers | Q73549313 | ||
| Splenectomy and hemopoietic stem cell transplantation for myelofibrosis | Q73709920 | ||
| Myelofibrosis with myeloid metaplasia | Q73712758 | ||
| Allogeneic hematopoietic stem cell transplantation for myelofibrosis | Q73812277 | ||
| Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Resea | Q77363568 | ||
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 | ||
| Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia | Q79817900 | ||
| Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens | Q80262366 | ||
| Outcome of allogeneic stem cell transplantation in patients with myelofibrosis | Q80538898 | ||
| Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases | Q80607021 | ||
| Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment | Q80866784 | ||
| Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia | Q81321013 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1023-1035 | |
| P577 | publication date | 2014-10-03 | |
| P1433 | published in | Hematology / Oncology Clinics of North America | Q15749192 |
| P1476 | title | Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease | |
| P478 | volume | 28 |
Search more.